Format
Sort by

Send to:

Choose Destination

Search results

Items: 2

1.

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?

Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH.

Hepatology. 2015 Feb;61(2):703-11. doi: 10.1002/hep.27609. Review.

PMID:
25412906
2.

FDA: Increased HBV reactivation risk with ofatumumab or rituximab.

Mitka M.

JAMA. 2013 Oct 23;310(16):1664. doi: 10.1001/jama.2013.281115. No abstract available.

PMID:
24150447

Supplemental Content

Loading ...
Write to the Help Desk